Evidence map›Paper›PMID 42622758›Full record

ArticlePituitary2026

Diagnostic value of the TRH test for central hypothyroidism in patients with pituitary and parasellar tumors: a single-center retrospective cross-sectional study.

Battsetseg Buyandalai, Tetsuya Takamizawa, Kazuhiko Horiguchi, Sho Sekiguchi, Masashi Yoshikawa, Takuya Watanabe, Yutaka Watanuki, Emi Ishida, Satoshi Yoshino, Shunichi Matsumoto and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Battsetseg Buyandalai *Division of Endocrinology and Metabolism, Department of Internal Medicine, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Tetsuya Takamizawa *Division of Endocrinology and Metabolism, Department of Internal Medicine, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Kazuhiko HoriguchiDivision of Endocrinology and Metabolism, Department of Internal Medicine, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan. k-hori@gunma-u.ac.jp.ORCID http://orcid.org/0000-0001-6844-6082
Sho SekiguchiDivision of Endocrinology and Metabolism, Department of Internal Medicine, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Masashi YoshikawaDivision of Endocrinology and Metabolism, Department of Internal Medicine, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Takuya WatanabeDivision of Endocrinology and Metabolism, Department of Internal Medicine, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Yutaka WatanukiDivision of Endocrinology and Metabolism, Department of Internal Medicine, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Emi IshidaLaboratory of Diabetes and Metabolic Disorders, Institute for Molecular and Cellular Regulation, Gunma University Graduate School of Medicine, Maebashi, 371-8511, Japan.
Satoshi YoshinoDivision of Endocrinology and Metabolism, Department of Internal Medicine, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Shunichi MatsumotoDivision of Endocrinology and Metabolism, Department of Internal Medicine, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Rei YamaguchiDepartment of Neurosurgery, Gunma University Graduate School of Medicine, Maebashi, 371-8511, Japan.
Masahiko TosakaDepartment of Neurosurgery, Gunma University Graduate School of Medicine, Maebashi, 371-8511, Japan.
Masanobu YamadaDivision of Endocrinology and Metabolism, Department of Internal Medicine, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Eijiro YamadaDivision of Endocrinology and Metabolism, Department of Internal Medicine, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan.

Funding

Japan Society for the Promotion of Science 16K19551Ministry of Health, Labour and Welfare 23FC1042
6 · The paper itself

Abstract

purposeThe utility and diagnostic interpretation of the thyrotropin-releasing hormone (TRH) test for diagnose central hypothyroidism (CeH) remain unclear.

methodTo understand the significance of TRH testing for the diagnosis of CeH we reviewed the medical charts of 105 patients who underwent TRH test (200 µg) and analyzed TSH values and responses in three groups. Group 1, the control group, included 25 participants without pituitary and parasellar tumors (PPTs), and with normal pituitary function. Group 2, the CeH group, included 13 patients with PPTs and low free thyroxine (fT4) levels. Group 3 included 67 patients with PPTs but normal fT4 levels.

resultsBasal TSH levels did not significantly differ between Group 1 and Group 2. After TRH test, a peak TSH value and fold-TSH response were significantly lower in Group 2. Group 2 showed a higher rate of delayed and prolonged TSH responses and lower fold-free triiodothyronine (fT3) responses. We determined the cut-off values of fold-TSH, prolonged response, and fold-fT3 responses for diagnosing CeH patients with high sensitivity and specificity. Using two or more of these cut-off values further reduced the false-positive rate to 4%. Group 3 had a higher rate of positive results than Group 1, suggesting that there are patients with hidden CeH.

conclusionIn this study, we revealed that CeH can be diagnosed with a TRH test with a probability of more than 90%, and the test may be useful for diagnosing the CeH in patients with normal fT4 levels.

Indexed as

HypothyroidismPituitary NeoplasmsThyrotropin-Releasing HormoneAdultAgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedRetrospective StudiesThyrotropinThyroxineTriiodothyronineThyrotropinThyrotropin-Releasing HormoneThyroxineTriiodothyronineCentral hypothyroidismParasellar tumorPituitary tumorSubclinical hypothyroidismThyrotropin releasing hormone test

Identifiers

PMID42622758

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.